PharmaDrug Restructures Debt to Strengthen Biopharma Pipeline
Toronto, Ontario – October 31, 2025 — PharmaDrug Inc. (CSE: PHRX; OTC Pink: LMLLF), a specialty pharmaceutical company focused...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Toronto, Ontario – October 31, 2025 — PharmaDrug Inc. (CSE: PHRX; OTC Pink: LMLLF), a specialty pharmaceutical company focused...
Miami, Florida – October 30, 2025 — Allosite Therapeutics, a biotechnology company pioneering allosteric integrin agonists for the treatment...
South San Francisco, Calif. – October 30, 2025 — BridgeBio Oncology Therapeutics, Inc. (BBOT) announced two poster presentations at...
BOSTON, October 29, 2025 — Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology leader in RNA medicines, has...
